Pancreatic Cancer

CHARLOTTE, N.C. — Pancreatic cancer screenings in high-risk individuals identified high-risk lesions in nearly 1% of patients and intermediate-risk pathology in more than 30%, according to data presented at the ACG Annual Scientific Meeting.

A new report from the American Association for Cancer Research demonstrated a 2.3% decrease in cancer deaths between 2016 and 2019.

The FDA granted orphan drug designation to ATG-101 for the treatment of pancreatic cancer, according to a press release from the agent’s manufacturer.

The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.

Cristina R. Ferrone, MD, has been appointed chair of the department of surgery at Cedars-Sinai.

Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among patients with previously resected pancreatic ductal adenocarcinoma, according to 5-year data from a randomized phase 3 study.

A recent study showed that neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy extended survival in patients with borderline resectable pancreatic cancer.

Neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy demonstrated favorable OS among patients with borderline resectable pancreatic cancer, according to results of a phase 2 trial published in JAMA Oncology.

Vaccinated patients with cancer had significantly higher risks for breakthrough COVID-19 infection, especially those undergoing active cancer care, compared with individuals without cancer, according to a study published in JAMA Oncology.

Here are Healio’s top 10 peer-tested articles from Digestive Disease Week 2022, which highlight research on restrictive diets, gallstone disease, dog ownership and Crohn’s disease, COVID-19 antibody response and more.